Supira Medical, Inc. is developing the Supira System, a percutaneous ventricular assist device (pVAD) designed to provide hemodynamic support for high-risk percutaneous coronary interventions (HRPCI) and cardiogenic shock (CS) patients.

Latigo Biotherapeutics develops non-opioid pain treatments, focusing on selective Nav1.8 inhibitors.

Garuda Therapeutics develops proprietary hematopoietic stem cell therapies that are self-renewing, HLA-compatible, and transgene-free for immediate patient availability.

Umoja Biopharma is a biotechnology company focused on developing in vivo CAR T cell therapies for oncology and autoimmune diseases using its VivoVec™ gene delivery technology.

Numab Therapeutics is a biotech company that develops multi-specific antibody-based immunotherapies for inflammation and cancer.

Orbis Medicines develops oral macrocycle drugs as alternatives to biologic drugs using their nGen platform, which combines automated chemistry and machine learning.

nChroma Bio develops innovative genetic medicines using epigenetic editing and non-viral delivery technologies to treat chronic hepatitis B and D.

Axonis Therapeutics is a biotechnology company developing novel neuromedicines targeting neurological disorders like epilepsy and pain.

Triveni Bio is a biotech company developing novel antibody treatments for immunological and inflammatory disorders.

GC Therapeutics (GCTx) develops off-the-shelf iPSC-based cell therapy products for gastrointestinal, neurological, and immunological diseases using their innovative TFome platform.

Supira Medical, Inc. is developing the Supira System, a percutaneous ventricular assist device (pVAD) designed to provide hemodynamic support for high-risk percutaneous coronary interventions (HRPCI) and cardiogenic shock (CS) patients.

Triveni Bio is a biotech company developing novel antibody treatments for immunological and inflammatory disorders.

Star Therapeutics is a biotechnology company that develops first-in-class antibody therapies, primarily for hematology and immunology, and also generates additional biotech companies focused on discovering and advancing novel antibody therapies.

FORE Biotherapeutics is a precision oncology company that focuses on the clinical development of plixorafenib, a novel small-molecule inhibitor for treating BRAF-altered tumors.

Rapport Therapeutics is a clinical-stage biotechnology company that develops precision neuromedicines for seizure and psychiatric disorders by targeting specific neuroanatomical regions, aiming to provide better alternatives to current treatments by reducing unwanted drug-target interactions.